Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;52(6):1113-1117.
doi: 10.1111/1346-8138.17752. Epub 2025 Apr 16.

Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year Study

Edoardo Mortato  1 , Lorenzo Marcelli  1 , Lorenzo Tofani  1 , Alfredo Belcastro  1 , Marina Talamonti  2 , Claudia Paganini  1 , Cosimo Di Raimondo  2 , Luca Bianchi  1   2 , Marco Galluzzo  1   2
Affiliations

Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year Study

Edoardo Mortato et al. J Dermatol. 2025 Jun.

Abstract

Psoriasis is associated with comorbidities like metabolic syndrome and nonalcoholic fatty liver disease, increasing the risk of liver fibrosis. This study evaluated the long-term effects of guselkumab on liver fibrosis in 154 psoriasis patients using the Fibrosis-4 (FIB-4) index, a noninvasive marker of fibrosis, over 3 years. Patients were stratified by baseline FIB-4 (≥ 1.3 or < 1.3) and age (35-65 years). Mean FIB-4 values remained stable across all subgroups, with no significant changes observed. High-risk patients (FIB-4 ≥ 1.3) showed minor, nonsignificant fluctuations, while low-risk patients (FIB-4 < 1.3) exhibited a mild, age-related upward trend. Disease duration emerged as a key factor influencing FIB-4, highlighting the importance of early treatment. These findings suggest guselkumab does not contribute to liver fibrosis progression in psoriasis patients. Further research with advanced methods like imaging or biopsy is needed to confirm the long-term hepatic safety of IL-23 inhibitors like guselkumab.

Keywords: Fibrosis‐4 index; IL‐23 inhibitors; guselkumab; liver fibrosis; psoriasis; psoriasis duration.

PubMed Disclaimer

References

    1. A. Ogdie, S. K. Grewal, M. H. Noe, et al., “Risk of Incident Liver Disease in Patients With Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population‐Based Study,” Journal of Investigative Dermatology 138 (2018): 760–767.
    1. K. Narayanasamy, A. D. Sanmarkan, K. Rajendran, C. Annasamy, and S. Ramalingam, “Relationship Between Psoriasis and Non‐Alcoholic Fatty Liver Disease,” Przegląd Gastroenterologiczny 11 (2016): 263–269.
    1. C. M. Maybury, H. F. Porter, E. Kloczko, et al., “Prevalence of Advanced Liver Fibrosis in Patients With Severe Psoriasis,” JAMA Dermatology 155 (2019): 1028–1032.
    1. R. K. Sterling, E. Lissen, N. Clumeck, et al., “Development of a Simple Noninvasive Index to Predict Significant Fibrosis in Patients With HIV/HCV Coinfection,” Hepatology (Baltimore, Md.) 43, no. 6 (2006): 1317–1325, https://doi.org/10.1002/hep.21178.
    1. L. Castera, M. Friedrich‐Rust, and R. Loomba, “Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease,” Gastroenterology 156 (2019): 1264–1281.

LinkOut - more resources